The company uses machine learning algorithms to analyze clinical data and identify the microbes that are effective in treating patients. They focus on developing cocktails of microbes that have already demonstrated safety and efficacy in humans, which reduces translational risk. Finch Therapeutics has a portfolio of microbiome assets, including CP101, a late-stage, investigational, orally administered microbiome candidate with positive clinical data from a Phase 2 trial. They also have pre-clinical assets that target ulcerative colitis, Crohn’s disease, and autism spectrum disorder. The company has a robust intellectual property estate, including more than 70 issued U.S. and foreign patents. In January 2023, Finch announced a decision to discontinue its Phase 3 trial of CP101 in recurrent CDI and focus on realizing the value of its intellectual property estate and other assets.